Forest Laboratories, Inc. to Present Cariprazine Data at the International College of Neuropsychopharmacology World Congress
June 20 2014 - 4:05PM
Business Wire
Forest Laboratories, Inc. (NYSE:FRX) today announced that data
on the investigational drug cariprazine will be presented at the
International College of Neuropsychopharmacology (CINP) 29th World
Congress, scheduled June 22-26, 2014 in Vancouver, Canada.
Mon. June 23, 5:15-6:45 PM PDT:
- Cariprazine Monotherapy in the
Treatment of Bipolar Depression: A Double-Blind,
Placebo-Controlled Study (poster #LP-01-005)
- Categorical Improvements in Severity
of Mania and Schizophrenia Symptoms: Pooled Analyses of
Cariprazine Phase II/III Trials (poster #P-03-014)
- Cariprazine Demonstrates Greater
Potency Than Aripiprazole In Animal Models of Psychosis, Cognitive
Impairment, and Negative Symptoms (poster #P-05-009)
- Safety and Tolerability of
Cariprazine in Long-Term Treatment of Schizophrenia: Integrated
Summary of Safety Data (poster #P-05-027)
Tues. June 24, 5:15-6:45 PM PDT:
- Cariprazine as Adjunctive Therapy in
Major Depressive Disorder: A Double-Blind, Placebo-Controlled
Study (poster #LP-02-009)
Wed. June 25, 5:15-6:45 PM PDT:
- Safety and Tolerability of
Cariprazine in Patients with Acute Bipolar Mania: Pooled Analysis
of 3 Phase II/III Pivotal Studies (poster #P-41-011)
About Cariprazine
Cariprazine, an investigational drug, is an orally active,
potent dopamine D3-preferring D3/D2 receptor partial agonist
atypical antipsychotic. It has a low affinity at other receptor
sites such as 5-HT2C, muscarinic, and adrenergic receptor sites.
Cariprazine is protected by a composition-of-matter patent that
expires in 2027 without patent term extension.
Cariprazine is being developed for the treatment of
schizophrenia and bipolar mania in adults. On November 21, 2013
Gedeon Richter Plc. and Forest announced that the U.S. Food and
Drug Administration issued a complete response letter regarding the
new drug application for schizophrenia and bipolar mania. In
addition, cariprazine is being investigated for the treatment of
bipolar depression and as adjunctive treatment for major depressive
disorder in adults.
Cariprazine was discovered by Gedeon Richter Plc. and is
licensed to Forest Laboratories, Inc., in the U.S. and Canada.
About Schizophrenia
Schizophrenia is a chronic and disabling disorder that affects
more than 2 million people in the U.S. It imposes significant
burden on patients, their families, and society. Symptoms fall into
three broad categories: positive symptoms (hallucinations,
delusions, thought disorders, and movement disorders), negative
symptoms (such as loss of motivation and social withdrawal), and
cognitive symptoms (problems with executive functioning, focusing,
and working memory).
About Bipolar I Disorder
Bipolar disorder, which encompasses bipolar I and bipolar II
disorders, affects approximately 5.7 million people in the U.S.
Bipolar I disorder, also known as manic-depressive illness, is
characterized by unusual shifts in mood, energy, activity levels,
and the ability to carry out day-to-day tasks. Patients experience
"mood episodes" that manifest as either a manic episode
(overexcited, extreme irritability, racing thoughts, and
difficulties with sleep) or a depressive episode (extreme sadness,
fatigue, or hopelessness), or a combination of both. Depression
that occurs in patients with bipolar disorder is called “bipolar
depression.”
About Major Depressive Disorder
MDD is a serious medical condition often requiring treatment,
affecting almost 16 million adults in the United States yearly or
approximately 7.3% of the adult U.S. population. MDD, also known as
depression, is a common debilitating disorder in which feelings of
sadness and other symptoms occur nearly every day for at least two
weeks and interfere with a person’s ability to work, sleep, study,
eat, and enjoy once-pleasurable activities. Among all medical
illnesses, MDD is a leading cause of disability in the U.S. The
World Health Organization predicts depression will become the
second leading cause of disability by the year 2020.
About Forest Laboratories
Forest Laboratories (NYSE:FRX) is a leading, fully integrated,
specialty pharmaceutical company largely focused on the United
States market. Forest markets a portfolio of branded drug products
and develops new medicines to treat patients suffering from
diseases principally in five therapeutic areas: central nervous
system, cardiovascular, gastrointestinal, respiratory, and
anti-infective. Forest’s strategy of acquiring product rights for
development and commercialization through licensing, collaborative
partnerships and targeted mergers and acquisitions allows Forest to
take advantage of attractive late-stage development and commercial
opportunities, thereby managing the risks inherent in drug
development. In January 2014, Forest acquired Aptalis
Pharmaceuticals for $2.9 billion in cash in order to gain access to
its GI and Cystic Fibrosis products, including treatments for
Ulcerative Proctitis, Duodenal Ulcers, H. Pylori, Anal Fissures,
and Pancreatic Insufficiency. In February 2014, Forest and Actavis
plc announced an agreement where Forest would be acquired for about
$25 billion in cash and stock. The acquisition of Forest by Actavis
is contingent upon regulatory and shareholder approvals.
Forest is headquartered in New York, NY. To learn more, visit
www.frx.com.
Except for the historical information contained herein, this
release contains forward-looking statements within the meaning of
the Private Securities Litigation Reform Act of 1995. These
statements involve a number of risks and uncertainties, including
the difficulty of predicting FDA approvals, the acceptance and
demand for new pharmaceutical products, the impact of competitive
products and pricing, the timely development and launch of new
products, and the risk factors listed from time to time in Forest
Laboratories' Annual Report on Form 10-K, Quarterly Reports on Form
10-Q, and any subsequent SEC filings. Forest assumes no obligation
to update forward-looking statements contained in this release to
reflect new information or future events or developments.
Forest Laboratories, Inc.Frank J. Murdolo, 212-224-6714Vice
President - Investor Relationsmedia.relations@frx.comorAmanda
KaufmanMedia Relationsamanda.kaufman@frx.com
Forest Road Acquisition (NYSE:FRX)
Historical Stock Chart
From May 2024 to Jun 2024
Forest Road Acquisition (NYSE:FRX)
Historical Stock Chart
From Jun 2023 to Jun 2024